Natriuretic peptide-guided levosimendan therapy for heart failure: a promising new approach.
Giamouzis
Grigorios
G
Giannakoulas
Georgios
G
Tsarpalis
Konstantinos
K
Agha
Syed A
SA
Georgiopoulou
Vasiliki
V
Kalogeropoulos
Andreas
A
Karvounis
Haralambos
H
Butler
Javed
J
D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage; D002316:Cardiotonic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004280:Dobutamine / Q000008:administration & dosage / Q000627:therapeutic use; D006333:Heart Failure / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D006835:Hydrazones / Q000008:administration & dosage / Q000627:therapeutic use*; D007262:Infusions, Intravenous; D020097:Natriuretic Peptide, Brain / Q000097:blood; D011237:Predictive Value of Tests; D011379:Prognosis; D011724:Pyridazines / Q000008:administration & dosage / Q000627:therapeutic use*; D000077464:Simendan; D013997:Time Factors
D000319:Adrenergic beta-Antagonists; D002316:Cardiotonic Agents; D006835:Hydrazones; D011724:Pyridazines; D020097:Natriuretic Peptide, Brain; D000077464:Simendan; D004280:Dobutamine